M1001 is a weak hypoxia-inducible factor-2α (HIF-2α) agonist. M1001 can bind to the HIF-2α PAS-B domain with Kd of 667 nM. M1001 may be utilized in chronic kidney disease study.

Physicochemical Properties

Molecular Formula	C17H17N3O2S
Molecular Weight	327.400782346725
Exact Mass	327.104
CAS #	874590-32-6
PubChem CID	4905675
Appearance	Light green to green solid powder
LogP	2.7
Hydrogen Bond Donor Count	1
Hydrogen Bond Acceptor Count	4
Rotatable Bond Count	3
Heavy Atom Count	23
Complexity	563
Defined Atom Stereocenter Count	0
SMILES	O=S1(C2C(=CC=CC=2)C(NC2C(N3CCCC3)=CC=CC=2)=N1)=O
InChi Key	LONXCUOJVJLTIP-UHFFFAOYSA-N
InChi Code	InChI=1S/C17H17N3O2S/c21-23(22)16-10-4-1-7-13(16)17(19-23)18-14-8-2-3-9-15(14)20-11-5-6-12-20/h1-4,7-10H,5-6,11-12H2,(H,18,19)
Chemical Name	1,1-dioxo-N-(2-pyrrolidin-1-ylphenyl)-1,2-benzothiazol-3-amine
Synonyms	M-1001; M 1001; M1001
HS Tariff Code	2934.99.9001
Storage	Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Shipping Condition	Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)

Biological Activity

ln Vitro	In 786-O cells, M1001 (10 μM) treatment resulted in enhanced expression of HIF-2 target genes [1]. M1001 (10 μM) demonstrates mild pulsatile effects upon binding to HIF-2α [1]. M1001 (1–10 μM)
Cell Assay	Western Blot Analysis[1] Cell Types: 786-O Cell Tested Concentrations: 10 μM Incubation Duration: Experimental Results: Moderate increase in expression of HIF-2 target genes in 786-O cells) Reduce VHL and HIF-2α combination [1]. . Western Blot Analysis[1] Cell Types: HEK293T Cell Tested Concentrations: 1 and 10 µM Incubation Duration: Experimental Results: diminished physical association between HIF-2α and VHL.
References	[1]. Bidirectional modulation of HIF-2 activity through chemical ligands. Nat Chem Biol. 2019 Feb 25.

Solubility Data

Solubility (In Vitro)

DMSO : ~250 mg/mL (~763.59 mM)

Solubility (In Vivo)

Solubility in Formulation 1: ≥ 2.33 mg/mL (7.12 mM) (saturation unknown) in 10% DMSO + 40% PEG300 +5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 23.3 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 + to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution.  (Please use freshly prepared in vivo formulations for optimal results.)

Preparing Stock Solutions		1 mg	5 mg	10 mg
	1 mM	3.0544 mL	15.2718 mL	30.5437 mL
	5 mM	0.6109 mL	3.0544 mL	6.1087 mL
	10 mM	0.3054 mL	1.5272 mL	3.0544 mL

*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.